Article
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Haematologica - 1 May 2013
Lange Thoralf, Ernst Thomas, Gruber Franz X, Maier Jacqueline, Cross Michael, Müller Martin C, Niederwieser Dietger, Hochhaus Andreas, Pfirrmann Markus
Abstract excerpt
The BCR-ABL T315I mutation causes resistance to imatinib, nilotinib and dasatinib in chronic myeloid leukemia. Forty BCR-ABL positive patients with imatinib resistance were analyzed for T315I mutated clones after six months on nilotinib or dasatinib treatment by quantitative allele-specific ligation polymerase chain reaction with a sensitivity of 0.05%. Ligation polymerase chain reaction revealed 10 patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.